VADERMIS

VIA DERMIS[™] is a minimally manipulated and acellular dermal matrix allograft that allows for supplemental support, protection, reinforcement, or covering of a tendon or soft tissue.

>> VIA DERMIS FEATURES AND BENEFITS¹

- Applied as reinforcement to help provide protection and extracellular matrix (ECM)/collagen framework while retaining intact vascular channels
- Versatile and flexible scaffold that can hold a suture
- Biocompatibility study demonstrated attachment and proliferation of:
 Fibroblast cells
 - Marrow-isolated adult multilineage inducible cells
 - Primary chondrocytes
- Variety of sizes and thicknesses

> VIA DERMIS PREPARATION

VIA DERMIS is produced using VIVEX's Integrity Processing[™], which reduces DNA and cellular material while preserving the inherent properties of dermal matrices, maintaining key extracellular matrix molecules, including collagen and elastin.¹ The extracellular matrix supports cellular infiltration, attachment, and proliferation.

The unique processing technique preserves the collagen and elastic tissue fibers while maintaining the open channels through which cells can migrate, proliferate, and form new blood vessels. This biologic process is crucial to the integration and remodeling of the allograft by host cells.

> NORMAL SKIN

The outer covering of the epidermis rests on the basement membrane, which is penetrated by epidermal appendages. Below the basement membrane is the dermis, a layer of dense **collagenous fibroconnective tissue** intermixed with elastic fibers. The dermis is penetrated by blood and lymphatic vessels, nerve endings, and epidermal appendages, such as sweat glands, hair follicles, and sebaceous glands. The dermis also contains mast cells, lymphocytes, and macrophages important to the immune system. **Elastic and collagen fibers** in the dermis are essential for maintaining the biomechanical properties of the skin.



Normal Skin





Collagen Fiber Stain

Elastin Fiber Stain



VIA DERMIS Non-Fenestrated





VIA DERMIS Wound Dehiscence



Sutured or Stapled

DERMAL ALLOGRAFT INTERACTION WITH WOUNDED SKIN²

During the first 24-48 hours after a dermal allograft is placed, it is separated from the damaged tissue by a thin film of fibrin and plasma until a vascular supply is re-established. In the next phase, a fine vascular network begins to form within the fibrin layer and allows for the transfer of some nutrients and oxygen. Over the next few days, the interface between the allograft and the damaged tissue transitions into revascularization with new blood vessels directly invading the dermal allograft. In total, these phases may take up to 5 days to incorporate the allograft.

> POTENTIAL APPLICATIONS FOR VIA DERMIS

Dermal allografts have been reported useful in many surgical and topical applications that include:

- Burns
- Amputations
- Rotator cuff reconstruction
- Hernia repairs

- Full thickness skin defects
- Wound dehiscence
- ACL reconstruction
- Bladder sling

- Deep voids
- Surgical repairs
- Oral reconstruction
- Dermal augmentation

- INDICATION FOR USE & STORAGE
 - · VIA DERMIS is intended for support, protection, reinforcement, and/or covering during applications
 - · Can hydrate in site or in saline prior to use
 - 5-year shelf life at ambient temperature storage

> ORDERING INFORMATION

CODE	DESCRIPTION	SIZE	THICKNESS
VDMF-THN-040400	VIA DERMIS [™] , Fenestrated	4x4cm	Thin (0.4-0.8mm)
VDMF-THN-040800	VIA DERMIS [™] , Fenestrated	4x8cm	Thin (0.4-0.8mm)
VDM-THN-040400	VIA DERMIS™	4x4cm	Thin (0.4-0.8mm)
VDM-THN-040800	VIA DERMIS™	4x8cm	Thin (0.4-0.8mm)
VDM-MED-040400	VIA DERMIS™	4x4cm	Medium (1.0-2.0mm
VDM-MED-040800	VIA DERMIS™	4x8cm	Medium (1.0-2.0mm
VDM-THK-040400	VIA DERMIS™	4x4cm	Thick (2.2-3.5mm)
VDM-THK-040800	VIA DERMIS™	4x8cm	Thick (2.2-3.5mm)

SAFE AND TRUSTED PARTNER

- · VIVEX Biologics is a regenerative solutions company, focusing on patient care through the innovation of tissue-based therapies.
- · All tissue is handled and processed in accordance with both FDA regulations and AATB standards.
- · With more than 50 years of highly safe and effective operations, VIVEX has endeavored to create treatment options and solutions that will improve clinical, surgical, and therapeutic patient outcomes.
- VIVEX maintains the trend of safely delivering over 2 million allografts with no disease transmission.

VIVEX Biologics will use reasonable efforts to provide accurate and complete information herein, but this information should not be construed as providing clinical advice. dictating reimbursement policy or as a substitute for the judgment of a health care provider. It is the health care provider's responsibility to determine the appropriate treatment, codes, charges for services and use of modifiers for services rendered and to submit coverage or reimbursement-related documentation

1. Data on file at Vivex Biologics, Inc.

2. Brunicardi FC et al. Schwartz's Principles of Surgery 9th ed., Chapter 45, Plastic and Reconstructive Surgery



2430 NW 116th Street, Miami, FL 33167 (888) 684-7783 | vivex.com | customercare@vivex.com . Trademarks [™] and Registered Trademarks [®] of 2021 Vivex Biologics, Inc. Copyright © 2021 Vivex Biologics, Inc. All rights reserved.







Epithelial side up